Agreed wimusky, IPCI's Rexista is the 1st to be bioequivalent to OxyContin and have no food effect...been a disappointing generics pathway over the past 3 years due to the FDA delays in ANDA approvals...but those days are finally behind us and now we have several impactful catalysts to IPCI's top and bottom lines in play:)